Pershing Square

Come people: wake up! Read more »

UBS, Deutsche Bank Join Team Ackman

Bill Ackman has been talking about freeing himself from the vagaries of investors always asking for their money back at the most inopportune times for years now. Sure, that permanent-capital IPO didn’t happen in late 2011, but this time, Bill is serious. Read more »

Bill Ackman’s Magical Year Continues

By no means has everything gone right for the Pershing Square Capital Management chief in 2014. His whole Herbalife-destroying performance actually lost him money, for one. But it’s pretty much the only thing that has lost him money this year. Sure, Allergan told him to piss off. But then the courts told Allergan to piss off itself and told Bill they’d be happy to hear what he had to say when he wanted to say it. Oh yea and he’s still way up on that whole mess, anyway. And just when he got to suing the government for refusing to do what he wants with Fannie Mae and Freddie Mac (and then suing them again), Burger King decided to buy a Canadian icon for tax purposes, making him a whole bunch more money. So, yea, Bill’s feeling pretty good right now. Read more »

The last two years were just a warm-up. Read more »

And whether or not they deserve the speedy attention of a court in Santa Ana, Calif. How’s a week from Wednesday sound? Read more »

Bill Ackman Doesn’t Need Your Pity

Not even a historic PR disaster leading to a 25% surge in the shares of its $1 billion short can keep Pershing Square down this year. Read more »

  • 05 Aug 2014 at 12:00 PM

Andrew Ross Sorkin Smells Something Fishy

Late last week, Botox-maker Allergan Inc sued Valeant Pharmaceuticals and Pershing Square, alleging the latter two had engaged in insider trading when Pershing bought $1 billion worth of Allergan shares ahead of a takeover offer by the hedge fund and Valeant. On the suggestion of wrongdoing, Valeant called with charges “baseless,” while Ackman stated in a press release that “This is a shameless attempt by Allergan to delay the shareholders’ fundamental right to call a special meeting and vote their shares. Allergan is threatened by our progress toward calling the special meeting. This scorched-earth approach is further evidence of the board’s and management’s further entrenchment.”

Not entirely convinced? Dealbook‘s Andrew Ross Sorkin, who in his column today says WAIT JUST A SECOND, PEOPLE. Read more »